Steven has extensive experience in therapeutic development in the biotechnology and pharmaceutical industries. He previously led research at Circuit Therapeutics, drug discovery at Signum Biosciences, headed the cellular neurodegeneration group at Wyeth/Pfizer, and was a program leader at AGY Therapeutics. In these roles he has led both small molecule and biological research and development programs across a diverse range of indications in the field of neuroscience. Steven is a graduate of the University of Cambridge, UK, received his PhD from the University of Bristol, UK and performed postdoctoral work at Stanford University. He also serves as an Adjunct Assistant Professor of Neurology at Rutgers University.
CSO at Alkahest, Inc.
Visit website: https://www.alkahest.com/steven-braithwaite/
See also: Alkahest - Biotechnology company focused on treating neurodegenerative and other age-related diseases
Steven Braithwaite is also referenced in the following:
Steven Braithwaite News
Super summary of 3rd Annual Longevity Therapeutics Summit
Lifespan.io (LEAF) - 16-Feb-2021
More and more companies making greater and greater progress - 2021 could be an exciting yearRead more...
Longevity Leaders' latest report on how longevity is disrupting the world
Longevity Leaders (LSX) - 01-Jan-2020
An interesting collection of interviews and white-papers with industry leadersRead more...